$5.03
0[0.00%]
At close: Apr 24
$5.03
0[0.00%]
PreMarket: 4:00PM EDT
Aurinia Pharmaceuticals
(NASDAQ:AUPH)Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Analyst Ratings, Price Targets, Predictions
Aurinia Pharmaceuticals Inc has a consensus price target of $8.6, established from looking at the 28 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on March 1, 2024, February 23, 2024, and February 22, 2024. With an average price target of $12 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 138.57% upside for Aurinia Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
RBC Capital
Oppenheimer
SVB Leerink
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aurinia Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/01/2024 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 158.45% | HC Wainwright & Co. | Ed Arce | → $13 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 98.81% | Cantor Fitzgerald | Olivia Brayer | $12 → $10 | Maintains | Overweight | Get Alert |
| 02/22/2024 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 158.45% | HC Wainwright & Co. | Ed Arce | $15 → $13 | Maintains | Buy | Get Alert |
| 02/16/2024 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 59.05% | RBC Capital | Douglas Miehm | $13 → $8 | Maintains | Outperform | Get Alert |
| 09/22/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 198.21% | HC Wainwright & Co. | Ed Arce | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 198.21% | HC Wainwright & Co. | Ed Arce | $14 → $15 | Maintains | Buy | Get Alert |
| 07/06/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 198.21% | Cantor Fitzgerald | Olivia Brayer | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 178.33% | HC Wainwright & Co. | Ed Arce | → $14 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 118.69% | RBC Capital | Douglas Miehm | → $11 | Reiterates | → Outperform | Get Alert |
| 01/04/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 118.69% | RBC Capital | Douglas Miehm | $10 → $11 | Maintains | Outperform | Get Alert |
| 11/07/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 178.33% | HC Wainwright & Co. | Ed Arce | $26 → $14 | Maintains | Buy | Get Alert |
| 11/04/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 98.81% | RBC Capital | Douglas Miehm | $18 → $10 | Maintains | Outperform | Get Alert |
| 11/04/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | — | Oppenheimer | Justin Kim | — | Downgrade | Outperform → Perform | Get Alert |
| 11/04/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 138.57% | SVB Leerink | Joseph Schwartz | $17 → $12 | Maintains | Outperform | Get Alert |
| 08/09/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 416.9% | HC Wainwright & Co. | Ed Arce | $30 → $26 | Maintains | Buy | Get Alert |
| 08/08/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 158.45% | Oppenheimer | Justin Kim | $15 → $13 | Maintains | Outperform | Get Alert |
| 05/05/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 397.02% | Cantor Fitzgerald | Olivia Brayer | → $25 | Assumes | → Overweight | Get Alert |
| 05/05/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 496.42% | HC Wainwright & Co. | Ed Arce | $33 → $30 | Maintains | Buy | Get Alert |
| 04/28/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.03 | 337.38% | RBC Capital | Douglas Miehm | $27 → $22 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Aurinia Pharmaceuticals (AUPH)?
The latest price target for Aurinia Pharmaceuticals (NASDAQ: AUPH) was reported by HC Wainwright & Co. on March 1, 2024. The analyst firm set a price target for $13.00 expecting AUPH to rise to within 12 months (a possible 158.45% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aurinia Pharmaceuticals (AUPH)?
The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ: AUPH) was provided by HC Wainwright & Co., and Aurinia Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Aurinia Pharmaceuticals (AUPH)?
The last upgrade for Aurinia Pharmaceuticals Inc happened on December 10, 2021 when Oppenheimer raised their price target to $31. Oppenheimer previously had a perform for Aurinia Pharmaceuticals Inc.
When was the last downgrade for Aurinia Pharmaceuticals (AUPH)?
The last downgrade for Aurinia Pharmaceuticals Inc happened on November 4, 2022 when Oppenheimer changed their price target from N/A to N/A for Aurinia Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Aurinia Pharmaceuticals (AUPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
Is the Analyst Rating Aurinia Pharmaceuticals (AUPH) correct?
While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a reiterated with a price target of $0.00 to $13.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $5.03, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.